Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAF<sup>V600E</sup> mutated, microsatellite-stable colon cancer. Here, BRAF is linked to malignant colon neoplasm.